ARMP Armata Pharmaceuticals Inc

Price (delayed)

$3.62

Market cap

$90.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.19

Enterprise value

$84.61M

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is ...

Highlights
ARMP's gross profit has surged by 60% since the previous quarter
The revenue has soared by 60% since the previous quarter
The company's quick ratio fell by 33% QoQ and by 21% YoY
The equity has contracted by 16% from the previous quarter and by 3.4% YoY

Key stats

What are the main financial stats of ARMP
Market
Shares outstanding
24.94M
Market cap
$90.27M
Enterprise value
$84.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.15
Price to sales (P/S)
29.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.96
Earnings
Revenue
$3.03M
EBIT
-$23.69M
EBITDA
-$22.58M
Free cash flow
-$21.14M
Per share
EPS
-$1.19
Free cash flow per share
-$0.85
Book value per share
$1.15
Revenue per share
$0.12
TBVPS
$1.81
Balance sheet
Total assets
$48.28M
Total liabilities
$19.66M
Debt
$13.07M
Equity
$28.62M
Working capital
$13.81M
Liquidity
Debt to equity
0.46
Current ratio
3.34
Quick ratio
3.17
Net debt/EBITDA
0.25
Margins
EBITDA margin
-746.1%
Gross margin
100%
Net margin
-795.8%
Operating margin
-783.4%
Efficiency
Return on assets
-51.7%
Return on equity
-90.8%
Return on invested capital
-73%
Return on capital employed
-55.9%
Return on sales
-783%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARMP stock price

How has the Armata Pharmaceuticals stock price performed over time
Intraday
-1.89%
1 week
-6.94%
1 month
-2.16%
1 year
20.27%
YTD
21.48%
QTD
-8.82%

Financial performance

How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$3.03M
Gross profit
$3.03M
Operating income
-$23.71M
Net income
-$24.08M
Gross margin
100%
Net margin
-795.8%
The company's net margin has surged by 99% YoY and by 33% QoQ
The company's operating margin has surged by 99% YoY and by 33% QoQ
ARMP's gross profit has surged by 60% since the previous quarter
The revenue has soared by 60% since the previous quarter

Growth

What is Armata Pharmaceuticals's growth rate over time

Valuation

What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.15
P/S
29.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.96
Armata Pharmaceuticals's EPS has increased by 38% YoY
ARMP's P/B is 85% above its 5-year quarterly average of 1.7
The equity has contracted by 16% from the previous quarter and by 3.4% YoY
ARMP's price to sales (P/S) is 64% lower than its last 4 quarters average of 81.9
The revenue has soared by 60% since the previous quarter

Efficiency

How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has surged by 99% YoY and by 33% QoQ
ARMP's return on invested capital is up by 36% year-on-year but it is down by 7% since the previous quarter
Armata Pharmaceuticals's ROA has increased by 10% YoY but it has decreased by 7% from the previous quarter
The company's return on equity fell by 8% QoQ and by 2% YoY

Dividends

What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARMP.

Financial health

How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 146% higher than its total liabilities
The company's quick ratio fell by 33% QoQ and by 21% YoY
ARMP's current ratio is down by 31% since the previous quarter and by 16% year-on-year
The company's debt is 54% lower than its equity
ARMP's debt to equity is up by 18% since the previous quarter and by 7% year-on-year
The equity has contracted by 16% from the previous quarter and by 3.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.